NHLBI Announces Participation in PA-10-056, Mentored Research Scientist Development Award (Parent K01)

Notice Number: NOT-HL-11-114

Key Dates
Release Date: January 14, 2011

Issued by
National Human Genome Research Institute (NHGRI), (https://www.genome.gov/)
National Heart, Lung, and Blood Institute (NHLBI), (http://www.nhlbi.nih.gov)
National Institute on Aging (NIA), (http://www.nia.nih.gov/)
National Institute on Alcohol Abuse and Alcoholism (NIAAA), (http://www.niaaa.nih.gov/)
National Institute of Allergy and Infectious Diseases (NIAID), (http://www.niaid.nih.gov/)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), (http://www.niams.nih.gov/)
National Institute of Biomedical Imaging and Bioengineering (NIBIB), (http://www.nibib.nih.gov/)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), (http://www.nichd.nih.gov/)
National Institute on Deafness and Other Communication Disorders (NIDCD), (http://www.nidcd.nih.gov)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), (http://www.niddk.nih.gov/)
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov/)
National Institute of Environmental Health Sciences (NIEHS), (http://www.niehs.nih.gov)
National Institute of Mental Health (NIMH), (http://www.nimh.nih.gov/)
National Institute of Neurological Disorders and Stroke (NINDS), (http://www.ninds.nih.gov/)
National Institute of Nursing Research (NINR), (http://ninr.nih.gov/)
National Center for Complementary and Alternative Medicine (NCCAM), (http://www.nccam.nih.gov/)
National Center for Research Resources (NCRR), (http://www.ncrr.nih.gov/)


This Notice is to inform potential applicants that the NHLBI announces its participation, effective February 12, 2011, in PA-10-056, "Mentored Research Scientist Development Award (Parent K01). The NHLBI seeks career training applications in the following focused research areas:

  • Highly innovative epidemiological research that elucidates the mechanisms, etiology, pathogenesis, prevention, diagnosis and treatment of heart, lung, blood diseases and sleep disorders.
  • Biostatistics research leading to the development of new methods for designing and analyzing clinical studies, including clinical trials, epidemiologic and genetics studies in heart, lung, blood diseases and sleep disorders.
  • Comparative effectiveness research that involves the comparison of screening, diagnostic, preventive or treatment strategies of heart, lung, blood diseases and sleep disorders using appropriate methods from randomized controlled trials to the analysis of electronic medical records.

The research project proposed must be relevant to the mission of the NHLBI and must be focused on one or more of the target areas listed above. Training should ensure that candidates develop relevant research skills, gain knowledge in state-of-the art concepts, and advanced methods and experimental approaches that will allow them to become independent investigators or play leading roles in these areas.

Professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds who wish to gain fundamental knowledge and develop research skills in biomedicine, bioengineering, bioimaging, or behavioral research should apply for the Mentored Quantitative Research Career Development Award (K25). The NHLBI also participates in the K08 and K23 programs that focus on research training for clinical scientists and clinically trained professionals who wish to conduct basic or patient-oriented research respectively.

The NHLBI does not support projects primarily focused on malignancy-related research. Studies that address a mechanistic correlation between cancer (i.e., lung cancer) and primary pulmonary diseases may be considered within the mission of the NHLBI. Applications on vaccine development will be considered outside NHLBI’s focused intent for this Funding Opportunity Announcement (FOA). Applications on respiratory pathogens will be considered within NHLBI’s intent for this FOA if studies focus on the host immune response. Other potential overlapping areas of interest shared by the NHLBI and other Institutes/Centers of the NIH include myeloproliferative and myelodysplastic disorders, hematological malignancies resulting from disruptions in hematopoiesis, and the use of hematopoietic stem cell transplantation and other cellular therapies. Therefore, applicants are strongly encouraged to contact the NHLBI before submitting an application to determine the NHLBI programmatic appropriateness for this FOA.

All other aspects of the FOA remain unchanged.


Lorraine M. Silsbee, M.H.S.
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, MSC 7936
Bethesda, MD 20892-7936 (Express mail zip: 20817)
Telephone: (301) 435-0709
FAX: (301) 480-1455
Email: silsbeeL@nhlbi.nih.gov

Jane D. Scott, ScD, MSN, FAHA
Director, Office of Research Training and Career Development,
Division of Cardiovascular Sciences (DCVS - responding for all NHLBI programmatic Divisions)
National Heart, Lung, and Blood Institute (NHLBI), NIH
Rockledge II, 8138, 6701 Rockledge Drive
Bethesda, Maryland 20892-7940
Telephone: (301) 435-0535
Email: scottj2@nhlbi.nih.gov